- Home
- DSGX vs BBIO Comparison
DSGX vs BBIO Comparison
Compare DSGX & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGX
- BBIO
- Stock Information
- Founded
- DSGX 1981
- BBIO 2015
- Country
- DSGX Canada
- BBIO United States
- Employees
- DSGX N/A
- BBIO N/A
- Industry
- DSGX Computer Software: Prepackaged Software
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- DSGX Technology
- BBIO Health Care
- Exchange
- DSGX Nasdaq
- BBIO Nasdaq
- Market Cap
- DSGX 9.0B
- BBIO 9.4B
- IPO Year
- DSGX 1999
- BBIO 2019
- Fundamental
- Price
- DSGX $93.90
- BBIO $52.86
- Analyst Decision
- DSGX Buy
- BBIO Strong Buy
- Analyst Count
- DSGX 8
- BBIO 16
- Target Price
- DSGX $122.75
- BBIO $64.44
- AVG Volume (30 Days)
- DSGX 474.8K
- BBIO 2.1M
- Earning Date
- DSGX 09-03-2025
- BBIO 11-11-2025
- Dividend Yield
- DSGX N/A
- BBIO N/A
- EPS Growth
- DSGX 14.17
- BBIO N/A
- EPS
- DSGX 1.69
- BBIO N/A
- Revenue
- DSGX $684,781,000.00
- BBIO $235,812,000.00
- Revenue This Year
- DSGX $11.78
- BBIO $115.97
- Revenue Next Year
- DSGX $13.45
- BBIO $65.50
- P/E Ratio
- DSGX $54.45
- BBIO N/A
- Revenue Growth
- DSGX 12.69
- BBIO 7.62
- 52 Week Low
- DSGX $91.00
- BBIO $21.72
- 52 Week High
- DSGX $124.31
- BBIO $54.60
- Technical
- Relative Strength Index (RSI)
- DSGX 37.32
- BBIO 56.31
- Support Level
- DSGX $91.00
- BBIO $51.85
- Resistance Level
- DSGX $104.44
- BBIO $53.81
- Average True Range (ATR)
- DSGX 2.27
- BBIO 1.62
- MACD
- DSGX -0.93
- BBIO 0.03
- Stochastic Oscillator
- DSGX 21.58
- BBIO 79.38
About DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.